12.01

1.56% -0.19

Tonix Pharmaceuticals Holding Corp (TNXP)

Overview News Price History Financials Why TNXP Down? Discussions Forecast Stock Split

Tonix Pharmaceuticals Holding Corp stock is traded at $12.01, with a volume of 567.03K. It is down -1.56% in the last 24 hours and down -15.78% over the past month. Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Previous Close:

$12.20

Open:

$12.48

24h Volume:

567.03K

Relative Volume:

1.16

Market Cap:

$191.45M

Revenue:

$13.11M

Net Income/Loss:

$-124.02M

P/E Ratio:

-0.8422

EPS:

-14.261

Net Cash Flow:

$-107.25M

1W Performance:

+12.77%

1M Performance:

-15.78%

6M Performance:

-34.05%

1Y Performance:

-65.01%

1-Day Range:

$11.89

$12.87

1-Week Range:

$10.41

$12.87

52-Week Range:

$10.03

$69.97

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile

Name

Tonix Pharmaceuticals Holding Corp

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

212-980-9155

Address

200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY

Employee

142

Twitter

@TONIXPharma

Next Earnings Date

2026-08-10

Latest SEC Filings

TNXP's Discussions on Twitter

Compare TNXP vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNXP Tonix Pharmaceuticals Holding Corp	12.01	191.45M	13.11M	-124.02M	-107.25M	-14.26
VRTX Vertex Pharmaceuticals Inc	451.63	114.63B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.13B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	34.65B	742.00K	-1.37B	-1.07B	-7.0731

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-18-22	Initiated	Noble Capital Markets	Outperform
Apr-18-19	Upgrade	ROTH Capital	Neutral → Buy
Aug-18-17	Upgrade	ROTH Capital	Neutral → Buy
Sep-07-16	Downgrade	ROTH Capital	Buy → Neutral
Feb-17-16	Reiterated	Oppenheimer	Outperform
Nov-04-15	Initiated	Cantor Fitzgerald	Buy
Jun-12-15	Initiated	Oppenheimer	Outperform
Feb-17-15	Reiterated	ROTH Capital	Buy
Sep-29-14	Reiterated	ROTH Capital	Buy

View All

Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News

Jun 19, 2026

Millennium Management LLC Increases Stake in Tonix Pharmaceutica - GuruFocus

Jun 19, 2026

Jun 18, 2026

Why TNXP Stock Is Suddenly Back On Retail Radar - Stocktwits

Jun 18, 2026